Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Accumulated Expenses (2016 - 2025)

Amphastar Pharmaceuticals has reported Accumulated Expenses over the past 13 years, most recently at $115.8 million for Q4 2025.

  • Quarterly results put Accumulated Expenses at $115.8 million for Q4 2025, down 8.52% from a year ago — trailing twelve months through Dec 2025 was $115.8 million (down 8.52% YoY), and the annual figure for FY2025 was $115.8 million, down 8.52%.
  • Accumulated Expenses for Q4 2025 was $115.8 million at Amphastar Pharmaceuticals, down from $150.3 million in the prior quarter.
  • Over the last five years, Accumulated Expenses for AMPH hit a ceiling of $198.7 million in Q2 2023 and a floor of $63.7 million in Q4 2022.
  • Median Accumulated Expenses over the past 5 years was $83.7 million (2021), compared with a mean of $102.2 million.
  • Biggest five-year swings in Accumulated Expenses: skyrocketed 198.38% in 2023 and later plummeted 49.96% in 2024.
  • Amphastar Pharmaceuticals' Accumulated Expenses stood at $67.3 million in 2021, then fell by 5.33% to $63.7 million in 2022, then grew by 6.57% to $67.9 million in 2023, then skyrocketed by 86.29% to $126.5 million in 2024, then dropped by 8.52% to $115.8 million in 2025.
  • The last three reported values for Accumulated Expenses were $115.8 million (Q4 2025), $150.3 million (Q3 2025), and $124.7 million (Q2 2025) per Business Quant data.